Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches
Open Access
- 1 May 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 9, 2575-2584
Abstract
Objective: Kirsten rat sarcoma (K-Ras) protein is a member of Ras family belonging to the small guanosine triphosphatases superfamily. The members of this family share a conserved structure and biochemical properties, acting as binary molecular switches. The guanosine triphosphate-bound active K-Ras interacts with a range of effectors, resulting in the stimulation of downstream signaling pathways regulating cell proliferation, differentiation, and apoptosis. Efforts to target K-Ras have been unsuccessful until now, placing it among high-value molecules against which developing a therapy would have an enormous impact. K-Ras transduces signals when it binds to guanosine triphosphate by directly binding to downstream effector proteins, but in case of guanosine diphosphate-bound conformation, these interactions get disrupted. Methods: In the present study, we targeted the nucleotide-binding site in the “on” and “off” state conformations of the K-Ras protein to find out suitable lead compounds. A structure-based virtual screening approach has been used to screen compounds from different databases, followed by a combinatorial fragment-based approach to design the apposite lead for the K-Ras protein. Results: Interestingly, the designed compounds exhibit a binding preference for the “off” state over “on” state conformation of K-Ras protein. Moreover, the designed compounds’ interactions are similar to guanosine diphosphate and, thus, could presumably act as a potential lead for K-Ras. The predicted drug-likeness properties of these compounds suggest that these compounds follow the Lipinski’s rule of five and have tolerable absorption, distribution, metabolism, excretion and toxicity values. Conclusion: Thus, through the current study, we propose targeting only “off” state conformations as a promising strategy for the design of reversible inhibitors to pharmacologically inhibit distinct conformations of K-Ras protein.Keywords
This publication has 48 references indexed in Scilit:
- Mutant KRAS is a druggable target for pancreatic cancerProceedings of the National Academy of Sciences, 2013
- Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase SignalingCancer Discovery, 2013
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patientsBritish Journal of Cancer, 2011
- Ras oncogenes: split personalitiesNature Reviews Molecular Cell Biology, 2008
- The structural basis for the transition from Ras-GTP to Ras-GDPProceedings of the National Academy of Sciences, 2002
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Ras family genes: An interesting link between cell cycle and cancerJournal of Cellular Physiology, 2002
- Small GTP-Binding ProteinsPhysiological Reviews, 2001
- Essential role for oncogenic Ras in tumour maintenanceNature, 1999
- Molecular Switch for Signal Transduction: Structural Differences Between Active and Inactive Forms of Protooncogenic ras ProteinsScience, 1990